DAPTA

CAS No. 106362-34-9

DAPTA( D-Ala-peptide T-amide; Adaptavir )

Catalog No. M29883 CAS No. 106362-34-9

DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 80 In Stock
10MG 140 In Stock
25MG 267 In Stock
50MG 399 In Stock
100MG 575 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock

Biological Information

  • Product Name
    DAPTA
  • Note
    Research use only, not for human use.
  • Brief Description
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.
  • Description
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.(In Vitro):DAPTA (1 nM) inhibits HIV-1 replication in monocytes/macrophages (M/M) by >90%. DAPTA blocks HIV entry and prevents HIV-1 infection. DAPTA reduces CCR5 mAb binding in human primary macrophages. DAPTA potently blocks R5 gp120-mediated neuronal apoptosis. DAPTA is even more potent in preventing neuronal apoptosis than the CCR5 antagonist TAK-779. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5. DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5. DAPTA inhibits the binding of gp120BaL/sCD4 to CCR5 (Cf2Th/synR5) cells with IC50 of 55 ± 0.08 pM.
  • In Vitro
    DAPTA (1 nM) inhibits HIV-1 replication in monocytes/macrophages (M/M) by >90%. DAPTA blocks HIV entry and prevents HIV-1 infection. DAPTA reduces CCR5 mAb binding in human primary macrophages. DAPTA potently blocks R5 gp120-mediated neuronal apoptosis. DAPTA is even more potent in preventing neuronal apoptosis than the CCR5 antagonist TAK-779. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5. DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5. DAPTA inhibits the binding of gp120BaL/sCD4 to CCR5 (Cf2Th/synR5) cells with IC50 of 55 ± 0.08 pM.
  • In Vivo
    ——
  • Synonyms
    D-Ala-peptide T-amide; Adaptavir
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    gp120BaL/sCD4-CCR5
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    106362-34-9
  • Formula Weight
    856.88
  • Molecular Formula
    C35H56N10O15
  • Purity
    >98% (HPLC)
  • Solubility
    H2O : 50 mg/mL (58.35 mM; Need ultrasonic)
  • SMILES
    ——
  • Chemical Name
    Sequence:Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH2

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Pollicita M, et al. Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells. Antivir Chem Chemother. 2007;18(5):285-95.
molnova catalog
related products
  • I-XW-053

    I-XW-053 is an inhibitor of capsid targeted HIV-1 replication using the hybrid structure based method to block the interface between CA N-terminal domains (NTD-NTD interface) with micromolar affinity.

  • Cyclotriazadisulfona...

    Cyclotriazadisulfonamide hydrochloride is a selective inhibitor of CD4-targeted HIV entry and inhibits the co-translational translocation of human CD4 into the ER lumen in a signal peptide-dependent way.

  • Pirmitegravir

    Pirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC.